Unlock instant, AI-driven research and patent intelligence for your innovation.

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

A C1-C4, C1-C4- technology, applied in the field of positive allosteric regulators of muscarinic acetylcholine receptor M4, can solve problems such as limiting clinical utility and the like

Active Publication Date: 2019-06-07
VANDERBILT UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Further, xanomeline was shown to reduce psychotic behavioral symptoms such as delusions, suspiciousness, vocal outbursts and hallucinations in Alzheimer's disease patients (Bodick et al., Arch. Neurol. [Archives of Psychiatry] 1997, 54, 465) , however treatment-induced side effects, e.g., gastrointestinal effects, severely limit the clinical utility of this compound

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Positive allosteric modulators of the muscarinic acetylcholine receptor m4
  • Positive allosteric modulators of the muscarinic acetylcholine receptor m4
  • Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Examples

Experimental program
Comparison scheme
Effect test

example 17

[0294] Example 1.7,9-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine (compound 1 )Synthesis

[0295] (3-Amino-4,6-dimethylthieno[2,3-b]pyridin-2-yl)(tetrahydro-2H-pyran-4-yl)methanone. In isopropanol (2mL ) to a mixture of 2-mercapto-4,6-dimethylnicotinecarbonitrile (50 mg, 0.30 mmol, 1 equiv) was added 2-bromo-1-(tetrahydro-2H-pyran-4-yl) Ethan-1-one (0.045 mL, 0.37 mmol, 1.2 equiv) and 10% potassium hydroxide (0.28 mL). After 10 minutes, the reaction was concentrated in vacuo. Purification by reverse phase HPLC gave 32 mg (37%) of the title compound. 1 H NMR (400MHz, DMSO-d 6 )δ7.76 (s, 2H), 7.08 (s, 1H), 3.92 (d, J = 11.1Hz, 2H), 3.45 (ddd, J = 11.0, 11.2, 3.0Hz, 2H), 2.97-2.91 (m ,1H),2.72(s,3H),2.52(s,3H),1.72-1.66(m,4H); ES-MS[M+1] + :291.2.

[0296] 7,9-Dimethyl-4-(tetrahydro-2H-pyran-4-yl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidine (Compound 1) To a mixture of Intermediate 1 (31 mg, 0.107 mmol, 1 equiv) and formamide (0.564 mL) in a v...

example 2

[0301] Example 2.8-Cyclohexyl-3,4-dimethylpyrimido[4',5':4,5]thieno[2,3-c]pyridazine (Compound 16)

[0302](5-Amino-3,4-dimethylthieno[2,3-c]pyridazin-6-yl)(cyclohexyl)methanone. To 3-mercapto-5 in isopropanol (8 mL) , to a mixture of 6-dimethylpyridazine-4-carbonitrile (200 mg, 1.21 mmol, 1 eq) was added 2-bromo-1-cyclohexylethan-1-one (0.175 mL, 1.45 mmol, 1.2 eq) and 10% potassium hydroxide (solution) (1.12 mL). After one hour, the reaction was concentrated in vacuo and used without further purification. ES-MS[M+1] + :290.2.

[0303] 8-cyclohexyl-3,4-dimethylpyrimido[4',5':4,5]thieno[2,3-c]pyridazine (16). Open to air heated to 150°C (5-Amino-3,4-dimethylthieno[2,3-c]pyridazin-6-yl)(cyclohexyl)methanone (350 mg, 1.21 mmol, 1 equivalent) and formamide in vials of (6.4 mL) was added formamidine acetate (1.26 g, 12.1 mmol, 10 equiv) in six equal portions over three hours. After an additional three hours, more formamidine acetate (1.26 g, 12.1 mmol, 10 equiv) was added. ...

example 3

[0309] Example 3. Biological Activity

[0310] A. Cell lines expressing muscarinic acetylcholine receptors

[0311] Use Lipofectamine2000 to human M 4 cDNA together with chimeric protein G qi5 Transfected into Chinese Hamster Ovary (CHO-K1) cells purchased from American Type Culture Collection. Will M 4 / G qi5 / CHO cells were cultured in Ham's F-12 medium containing 10% heat-inactivated fetal bovine serum (FBS), 20 mM HEPES, 500 μg / mL G418 sulfate and 200 μg / mL hygromycin B.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are pyrido[3',2':4,5]thieno[3,2-d]pyrimidine and pyrimido[4',5':4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to US Application Serial No. 62 / 418,663, filed November 7, 2016, which is incorporated herein by reference in its entirety. [0003] Statement of Government Interest [0004] This invention was made with Government support under Grant No. 1U19MH106839-01 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] The present disclosure relates to compounds, compositions and methods for the treatment of neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction. Background technique [0006] Cholinergic neurotransmission involves the activation of nicotinic acetylcholine receptors (nAChR) or muscarinic acetylcholine receptors (mAChR) through the binding of the endogenous orthosteric site agonist acetylcholine (ACh). Conditions associated with cognitive impairment, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4365C07D495/04
CPCC07D495/14A61K45/06A61K31/519A61P25/00A61P25/04A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28A61P43/00A61K2300/00C07D495/04
Inventor C·W·林斯利D·W·恩格尔斯P·J·康恩K·A·博林格R·卡普斯蒂克P·斯皮林S·R·博林格
Owner VANDERBILT UNIV